New SMC advice published

The has accepted the following drugs for use within NHS Scotland:

  • bendamustine hydrochloride (Levact) for chronic lymphocytic leukaemia when fludarabine not appropriate.
  • sunitinib (Sutent) for unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in patients receiving best supportive care, including somatostatin analogues if required for symptomatic control.
  • ticagrelor (Brilique) in combination with aspirin for the prevention of atherothrombotic events in acute coronary syndromes (including patients managed medically, with percutaneous coronary intervention or with CABG).
  • sevalamer carbonate (Renvela) for hyperphosphataemia in patients on haemodialysis. Use is restricted to second-line treatment.
  • iron isomaltoside 1000 (Monofer) for treatment of iron-deficiency anaemia with intolerance/resistance to oral iron or the need to deliver iron rapidly. Use is restricted to administration by high dose infusion and excludes patients receiving haemodialysis.

The SMC rejected botulinum toxin A (Botox) for use in migraine prophylaxis, calcium acetate and magnesium carbonate (Osvaren) and tocofersolan (Vedrop) following full submissions. Ethinylestradiol/drosperinone (Yasmin) and quetiapine prolonged release and immediate release (Seroquel XL and Seroquel) for the treatment of major depressive episodes in bipolar disorder were rejected following resubmissions.  

Further information:

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in